Effects of calcium channel blockers on in vivo cellular immunity in mice.
In vitro studies have shown that calcium channel blockers (CCB) inhibit lectin-induced lymphocyte proliferation. However, no in vivo effects have been documented yet. In this study we evaluated the effects of CCB on in vivo cellular immunity by using contact sensitivity to oxazolone in mice. From 15 to 30 twelve-week-old female C3H mice were randomized into: 0.9 NS (sham), ethanol, CsA, dexamethasone (DXM), verapamil, diltiazem, and nifedipine groups. These study agents were given daily from day 1 to day 9 subcutaneously to the shaved abdominal wall. The mice were sensitized with oxazolone to the abdominal wall on day 2 and challenged with oxazolone on the right ear on day 8. Delayed-type hypersensitivity was measured on day 10 and defined as the difference in thickness between the right (challenged) and left (control) ear of each mouse. The mean DTH of each study group was compared with that of the sham, and the statistical significance was determined by a Student's t test. The percentage of change in DTH from the sham was also calculated as: (mean DTH of study drug group-mean DTH of sham group)/mean DTH of sham group x 100%. A negative value meant a suppressive effect on DTH; a positive value, an enhancing one. The CsA, DXM, and nifedipine all had significant suppressive effects on DTH. Verapamil had a significant enhancing effect. Ethanol and diltiazem had no significant effect. More studies employing other antigens with several other cell-mediated response measurements along with DTH quantification should be done in order to determine the specificity of the immunosuppressive effect of CCB as well as the potential of any calcium antagonist as an adjuvant suppressive agent.
Corteza
Q
Q
Department of Medicine, University of Maryland Hospital, Baltimore 21201.
Shen
S
S
Revie
D
D
Chretien
P
P
D000818:Animals; D002121:Calcium Channel Blockers / Q000008:administration & dosage*; D003524:Cyclosporins / Q000008:administration & dosage; D003877:Dermatitis, Contact / Q000209:etiology / Q000276:immunology* / Q000473:pathology; D003907:Dexamethasone / Q000008:administration & dosage; D004110:Diltiazem / Q000008:administration & dosage; D004431:Ear, External; D000431:Ethanol / Q000008:administration & dosage; D005260:Female; D007111:Immunity, Cellular / Q000187:drug effects*; D051379:Mice; D008809:Mice, Inbred C3H; D009543:Nifedipine / Q000008:administration & dosage; D014700:Verapamil / Q000008:administration & dosage
D002121:Calcium Channel Blockers; D003524:Cyclosporins; D000431:Ethanol; D003907:Dexamethasone; D014700:Verapamil; D004110:Diltiazem; D009543:Nifedipine